PGIM Jennison Health Sciences Fund
Data updated: 2026-07-27
C000012122 — PGIM Jennison Health Sciences Fund. United States Large Cap Blend / Core Health Care Equity. Holdings, fees, performance and SEC filings.
C000012122 Fund Overview
PGIM Jennison Health Sciences Fund is a US mutual fund managed by Prudential Sector Funds, Inc., categorised as United States Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Prudential Sector Funds, Inc.
- Category: United States Large Cap Blend / Core Health Care Equity
- Assets under management: $1.39B
- SEC CIK: 0000352665
- SEC series ID: S000004380
- Share class ID: C000012122
C000012122 Investment Objective and Strategy
PGIM Jennison Health Sciences Fund describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Prudential Sector Funds, Inc..
Investment objective
The investment objective of the Fund is long-term capital appreciation .
Principal investment strategy
The Fund seeks investments whose prices will increase over time. The Fund normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The term investable assets refers to the Fund's net assets plus any borrowings for investment purposes. The Fund's investable assets will be less than its total assets to the extent that it has borrowed money for non-investment purposes, such as to meet anticipated redemptions. The Fund will invest in securities of issuers among a number of different countries throughout the world, one of which may be the United States.
However, the Fund has no limit on the amount of assets that must be invested in each country. The Funds investments in the securities of non-US issuers, which we refer to as foreign securities, include stocks and other equity-related securities. We refer to the group of industries in which the Fund concentrates as its sector. The Fund may have two separate segments that we call the Strategically Managed portfolio and the Enhanced Index portfolio. Currently, the Fund has all of its assets in a single Strategically Managed portfolio, and has no Enhanced Index portfolio segment. The Strategically Managed portfolio holds those equity and equity-related securities in which the portfolio managers have a high level of conviction for outperformance in the intermediate and long term and believe have limited downside potential in the short term.
Equity and equity-related securities in which the Fund primarily invests are common stocks, nonconvertible preferred stocks and convertible securities. The portfolio managers use fundamental and quantitative analyses to select individual securities, and they may invest more than 5% of the Fund's assets in any one issuer. The Fund participates in the initial public offering (IPO) market. For the Strategically Managed portfolio, the investment subadviser considers selling or reducing a stock position when, in the opinion of the investment subadviser, the stock has experienced a fundamental disappointment in earnings; the stock has experienced adverse price movement; the stock has reached an intermediate-term price objective and its outlook no longer seems sufficiently promising; or a relatively more attractive stock emerges.
An Enhanced Index portfolio would contain securities selected from a benchmark index made up of securities of that Fund's sector from the Standard & Poor's (S&P) Composite 1500 Index. The S&P Composite 1500 Index is made up of the S&P 500 Composite Stock Price Index (S&P 500), the S&P MidCap 400 Stock Index and the S&P SmallCap 600 Index. Under an Enhanced Index strategy, the subadviser would seek to outperform the benchmark index and to limit the possibility of significantly underperforming that benchmark. Enhanced Index portfolios are expected to hold a representative sample of the securities in the benchmark index and to over-weight or under-weight selected securities based upon proprietary quantitative models. The portfolio managers would try to control the risk of significantly underperforming the benchmark by keeping size and industry weightings relatively close to those in the benchmark.
Because the S&P 500 makes up 90% of the benchmark index's market capitalization, large-cap stocks may dominate the Fund's portfolio, particularly under an Enhanced Index strategy.
C000012122 Holdings
Top 10 holdings of PGIM Jennison Health Sciences Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Company | 17.35% |
| Merck & Company, Inc. | 6.06% |
| Unitedhealth Group, Inc. | 5.87% |
| Thermo Fisher Scientific, Inc. | 4.56% |
| Argenx SE | 3.55% |
| Vertex Pharmaceuticals, Inc. | 3.37% |
| Danaher Corp. | 3.28% |
| Intuitive Surgical, Inc. | 3.07% |
| Lonza Group AG | 3.02% |
| Cvs Health Corp. | 2.52% |
C000012122 Portfolio Allocation
Asset-class allocation of PGIM Jennison Health Sciences Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 97.8% |
| Cash & Equivalents | 3.8% |
C000012122 Costs and Fees
C000012122 costs about $222 per $10,000 invested per year in fund expenses.
- Net expense ratio: 2.22%
- Gross expense ratio: 2.22%
- Portfolio turnover: 81%
- Brokerage commissions: 6.92 bps of average net assets (SEC N-CEN)
C000012122 Cashflows
Over the 12 months to 2026-05, PGIM Jennison Health Sciences Fund had net outflows of $161.92M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-05 | −$24.47M |
| 2026-04 | −$19.95M |
| 2026-03 | −$19.65M |
| 2026-02 | −$14.99M |
| 2026-01 | −$17.15M |
| 2025-12 | $130.36M |
C000012122 Debt Constituents
No individual debt constituents are reported in PGIM Jennison Health Sciences Fund's latest SEC N-PORT filing.
C000012122 Prospectus and SEC Filings
Official PGIM Jennison Health Sciences Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-01-28
- Prospectus (485BPOS) — filed 2024-01-26
- Prospectus (485BPOS) — filed 2023-01-26
- Portfolio holdings (N-PORT) — filed 2026-07-27
- Portfolio holdings (N-PORT) — filed 2026-04-23
- Portfolio holdings (N-PORT) — filed 2026-01-28
- Annual census (N-CEN) — filed 2026-02-10
- Annual census (N-CEN) — filed 2025-02-11
Related Funds
Other United States Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.